LNCAROD (LncRNA Activating Regulator Of DKK1)

The results suggest that many UNTs can transcriptionally regulate genes, and this regulation is highly cancer- and species-specific. Because UNTs are widely expressed in cancer and other diseased cells, they may be an important class of transcriptional regulators. Their cell and species specificity may help explain inconsistencies across studies and species and make them potential disease-specific targets.

This finding presents a novel approach to the clinical management of HSCC, indicating that metformin influences various processes related to the growth and progression of HSCC. Specifically, it reduces lncAROD expression and inhibits tumor progression, suggesting that lncAROD may serve as a valuable biomarker for evaluating the prognosis of HSCC.

LNCAROD is specifically highly expressed in LUSC cells and tissues and may be a tumor-suppressor gene. The findings contribute to a deeper understanding of the function of LNCAROD in LUSC, and it may serve as a potential prognostic marker for personalized medical diagnosis in clinical practice.

Our findings enhance the understanding of m6A-modified lncRNA-driven machinery in ESCC radioresistance and underscore the significance of LNCAROD in this context, thereby contributing to the development of a potential therapeutic target for ESCC patients.

It may serve as a potential diagnostic and therapeutic target in GC. In addition, LNCAROD may function through the possible regulatory axis in GC development.